Risk stratification and patient counseling for natalizumab in multiple sclerosis

Neurology

Volumn 78, Issue 6, 2012, Pages 436-437

  Fox, Robert J ^a   Rudick, Richard A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

JC VIRUS ANTIBODY; NATALIZUMAB; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ANTIBODY DETECTION; ARTICLE; CLINICAL ARTICLE; DRUG SAFETY; FALSE NEGATIVE RESULT; HUMAN; JC VIRUS; MULTIPLE SCLEROSIS; PATIENT COUNSELING; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RISK ASSESSMENT; SEROLOGY; VIRUS ENCEPHALITIS;

EID: 84858147904     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e318245d2d0     Document Type: Article

References (7)

1. Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006;354:924-933.
2. Tyler KL. Progressive multifocal leukoencephalopathy: can we reduce risk in patients receiving biological immunomodulatory therapies? Ann Neurol 2010;68:271-274.
3. Medical Information, Biogen Idec. TYSABRI PML safety update. Available at: https://medinfo.biogenidec.com. Accessed July 8, 2011.
4. Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 2010;68:295-303.
5. Medical Information, Biogen Idec. TYSABRI (natalizumab): seroprevalence to anti-JCV antibodies: literature review and research status with the Biogen Idec and Elan 2-Step Test. Available at: https://medinfo.biogenidec.com. Accessed July 8, 2011.
6. Britt RR. The odds of dying: LiveScience: environment. Available at: http://www.livescience.com/3780-odds-dying.html. Accessed December 26, 2011.
7. Heesen C, Kleiter I, Nguyen F, et al. Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists. Mult Scler 2010;16:1507-1512.